News

GlobalData on MSN1d
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...
BioWorld6d
New IRAK-4-targeting PROTACs reported in Gan & Lee Pharmaceuticals patent
Gan & Lee Pharmaceuticals Co. Ltd. has discovered proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding agent coupled to interleukin-1 receptor-associated kinase 4 ...
Targeted Oncology1d
FDA Accepts NDA for Vepdegestrant in ER+/HER2- Metastatic Breast Cancer
The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...
Pharmabiz1d
US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer
US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...
MPR1d
Vepdegestrant Under Review for ER+/HER2- Breast Cancer With ESR1 Mutation
Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...
Arvinas Reports Second Quarter 2025 Financial Results And Provides Corporate Update
Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ...
GEN - Genetic Engineering and Biotechnology News2h
Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration
Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.